Read by QxMD icon Read

Nicolaus Kröger

Kavita Raj, Diderik-Jan Eikema, Donal P McLornan, Eduardo Olavarria, Henric-Jan Blok, Stefania Bregante, Fabio Ciceri, Jakob Passweg, Per Ljungman, Nicolaas Schaap, Kristina Carlson, Tsila Zuckerman, Liesbeth C de Wreede, Liisa Volin, Yener Koc, J Diez-Martin, Peter Brossart, Dominik Wolf, Didier Blaise, Paolo Di Bartolomeo, Antonin Vitek, Marie Robin, I Yakoub-Agha, Yves Chalandon, Nicolaus Kroger
This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow Transplantation database. The median age was 57 years (range, 38 to 72); 75% had primary MF and 25% had secondary MF. JAK2 V617F was mutated in 61%. Donors were HLA mismatched at 2 or more loci. Stem cells were sourced from bone marrow in 66% and peripheral blood in 34%. The median CD34+ cell dose was 4.8 × 106 /kg (range, 1.7 to 22...
November 5, 2018: Biology of Blood and Marrow Transplantation
J Canaani, E Beohou, M Labopin, A Ghavamzadeh, D Beelen, R-M Hamladji, D Niederwieser, L Volin, M Markiewicz, R Arnold, G Mufti, G Ehninger, G Socié, N Kröger, M Mohty, A Nagler
BACKGROUND: Outcomes for patients with acute myeloid leukaemia (AML) undergoing allogeneic stem cell transplantation (allo-SCT) have significantly improved in recent years. OBJECTIVES: To assess the incremental improvement of transplanted AML patients in the last two decades. METHODS: Patients included in this analysis were adult AML patients who underwent allo-SCT from an HLA-matched sibling donor (MSD) or HLA-matched unrelated donor (MUD) in first remission...
October 29, 2018: Journal of Internal Medicine
Eolia Brissot, Myriam Labopin, Gerhard Ehninger, Matthias Stelljes, Arne Brecht, Arnold Ganser, Johanna Tischer, Nicolaus Kröger, Boris Afanasyev, Jürgen Finke, Ahmet Elmaagacli, Hermann Einsele, Mohamad Mohty, Arnon Nagler
Primary refractory or relapsed acute myeloid leukemia is associated with dismal prognosis. Allogeneic stem cell transplantation is the only therapeutic option that offers prolonged survival and cure in this setting. In the absence of a matched sibling donor, transplantation from unrelated 10/10 or 9/10 and haploidentical donors are potential alternatives. The current study aimed to compare the outcomes of acute myeloid leukemia patients with active disease who received allogeneic stem cell transplantation from a haploidentical donor with post-transplant cyclophosphamide (n=199) versus an unrelated donor 10/10 (n=1111) and versus unrelated donor 9/10 (n=383) between 2007 and 2014 and reported to the EBMT registry...
October 25, 2018: Haematologica
Tim J Hartung, Leon P Sautier, Angela Scherwath, Kirsten Sturm, Nicolaus Kröger, Uwe Koch, Anja Mehnert
BACKGROUND: Although hematological cancer survivors have a high risk of disability, data on work-related issues are scarce for this population. METHODS: We investigated return to work (RTW) and work ability (Work Ability Index, WAI) in hematological cancer patients 6 months and 1 year after cancer treatment. We explored associations between baseline sociodemographic and medical characteristics and RTW as well as work ability at follow-up. RESULTS: The participation rate was 42% (baseline n = 91, after 12 months n = 40 (44%))...
2018: Oncology Research and Treatment
Firoozeh Sahebi, Laurent Garderet, Abraham S Kanate, Diderik-Jan Eikema, Nina Simone Knelange, Omar F Dávila Alvelo, Yener Koc, Didier Blaise, Qaiser Bashir, José M Moraleda, Peter Dreger, James F Sanchez, Stefan Ciurea, Harry Schouten, Nirav N Shah, Mareike Verbeek, Wolf Rösler, Jose L Diez-Martin, Stefan Schoenland, Anita D'Souza, Nicolaus Kröger, Parameswaran Hari
Allogeneic hematopoietic cell transplantation (allo-HCT) using siblings and matched donors has the potential for long-term disease control in a subset of high-risk patients with multiple myeloma (MM); however, the data on using haploidentical donors in this disease are limited. We conducted a retrospective analysis to examine the outcomes of patients with MM who underwent haploidentical allo-HCT within European Society for Blood and Marrow Transplantation/Center for International Blood and Marrow Transplant Research centers...
September 20, 2018: Biology of Blood and Marrow Transplantation
Marie Robin, Raphaël Porcher, Annalisa Ruggeri, Didier Blaise, Christine Wolschke, Linda Koster, Emanuele Angelucci, Friedrich Stölzel, Victoria Potter, Ibrahim Yakoub-Agha, Yener Koc, Fabio Ciceri, Jürgen Finke, Hélène Labussière-Wallet, Maria Jesús Pascual Cascon, Mareike Verbeek, Alessandro Rambaldi, Jan J Cornelissen, Patrice Chevallier, Rohini Radia, Arnon Nagler, Nathalie Fegueux, Eliane Gluckman, Theo de Witte, Nicolaus Kröger
Recently, haploidentical transplantation (haplo) using post-transplant cyclophosphamide (PTCy) has been reported to give very encouraging results in patients with hematological malignancies. Patients who have no HLA-matched donor currently have the choice between a mismatched unrelated donor, an unrelated cord blood (CB) donor, and a haploidentical related donor. The aim of our study is to compare the outcome of patients with myelodysplastic syndrome (MDS) who have been transplanted from a haploidentical donor using PTCy, an HLA-mismatched unrelated donor (marrow or peripheral blood stem cells), or an unrelated mismatched CB donor...
August 30, 2018: Biology of Blood and Marrow Transplantation
Matthew J Hartwell, Umut Özbek, Ernst Holler, Anne S Renteria, Hannah Major-Monfried, Pavan Reddy, Mina Aziz, William J Hogan, Francis Ayuk, Yvonne A Efebera, Elizabeth O Hexner, Udomsak Bunworasate, Muna Qayed, Rainer Ordemann, Matthias Wölfl, Stephan Mielke, Attaphol Pawarode, Yi-Bin Chen, Steven Devine, Andrew C Harris, Madan Jagasia, Carrie L Kitko, Mark R Litzow, Nicolaus Kröger, Franco Locatelli, George Morales, Ryotaro Nakamura, Ran Reshef, Wolf Rösler, Daniela Weber, Kitsada Wudhikarn, Gregory A Yanik, John E Levine, James Lm Ferrara
No abstract text is available yet for this article.
August 23, 2018: JCI Insight
Marco Ladetto, Sebastian Böttcher, Nicolaus Kröger, Michael A Pulsipher, Peter Bader
Relapse is the major cause of treatment failure after stem cell transplantation. Despite the fact that relapses occurred even if transplantation was performed in complete remission, it is obvious that minimal residual disease is present though not morphologically evident. Since adaptive immunotherapy by donor lymphocyte infusion or other novel cell therapies as well as less toxic drugs, which can be used after transplantation, the detection of minimal residual disease (MRD) has become a clinical important variable for outcome...
August 16, 2018: Bone Marrow Transplantation
Helen Baldomero, Mahmoud Aljurf, Syed Z A Zaidi, Shahrukh K Hashmi, Ardeshir Ghavamzadeh, Alaa Elhaddad, Rose-Marie Hamladji, Parvez Ahmed, Lamia Torjemane, Miguel Abboud, Abdelghani Tbakhi, Murtadha Al Khabori, Asma El Quessar, Nosa Bazuaye, Mohamed Amine Bekadja, Salman Adil, Omar Fahmy, Mani Ramzi, Ahmed Ibrahim, Amal Alseraihy, Nour Ben Abdejalil, Mahmoud Sarhan, Mohammed Al Huneini, Lahoucine Mahmal, Hassan ElSolh, Fazal Hussain, Amr Nassar, Hani Al-Hashmi, Amir Ali Hamidieh, Marcelo Pasquini, Yoshihisa Kodera, Nicolaus Kröger, Mohamed Mohty, Gregorio Jaimovich, Juliana Martinez Rolon, Kristjan Paulson, Hildegard Greinix, Daniel Weisdorf, Mary Horowitz, José Nunez, Alois Gratwohl, Jacob Passweg, Mickey Koh, Jeff Szer, Dietger Niederwieser, Nicolas Novitzky
Hematopoietic Stem Cell Transplantation (HSCT) activity was evaluated in the African (AFR)/EMRO region and compared to the global activity for the years 2006-2013. Data were obtained from 1570 teams in the 6 WHO continental regions. Of these, 29 (1.85%) of all teams were active in 12 of the 68 AFR/EMRO countries. They reported 2.331 (3.3%) of the worldwide 71.036 HSCT, and a transplant rate of 32.8 (TR; HSCT/10 million inhabitants; worldwide 128.5). This reflects still the lowest regional TR despite an increase of 90% since 2006...
August 6, 2018: Bone Marrow Transplantation
Yi-Bin Chen, Philip L McCarthy, Theresa Hahn, Sarah A Holstein, Masumi Ueda, Nicolaus Kröger, Michael Bishop, Marcos de Lima
Relapse is a major cause of treatment failure after stem cell transplantation. Novel agents given as maintenance or preemptive post transplant were discussed at the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse after Stem Cell Transplantation in Hamburg/Germany in November 2016 under the auspices of EBMT and ASBMT. Maintenance therapy is started after SCT without detectable disease, while preemptive therapy is triggered by the detection of minimal residual disease (MRD). The maintenance approach treats all patients, and overtreats a significant amount...
July 23, 2018: Bone Marrow Transplantation
Francis Ayuk, Dietrich W Beelen, Martin Bornhäuser, Matthias Stelljes, Tatjana Zabelina, Jürgen Finke, Guido Kobbe, Daniel Wolff, Eva-Maria Wagner, Maximilian Christopeit, Christoph Schmid, Hellmut Ottinger, Christoph Groth, Christoph Faul, Hartmut Bertz, Elena Rachlis, Christine Wolschke, Johannes Schetelig, Peter A Horn, Joannis Mytilineos, Martina Guellstorf, Reinhard Kelsch, Katharina Fleischhauer, Nicolaus Kröger, Wolfgang Bethge
Increasing donor-recipient HLA disparity is associated with negative outcomes of allogeneic hematopoietic stem cell transplantation (HSCT), but its comparative relevance amid non-HLA donor characteristics is not well established. We addressed this question in 3215 HSCTs performed between 2005 and 2013 in Germany for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Donors were HLA-matched related (MRD; n = 872) or unrelated (10/10 MUD, n = 1553) or HLA-mismatched unrelated (<10/10 MMUD, n = 790)...
July 24, 2018: Biology of Blood and Marrow Transplantation
Ioanna Triviai, Silke Zeschke, Jan Rentel, Marios Spanakis, Theo Scherer, Razif Gabdoulline, Victoria Panagiota, Felicitas Thol, Michael Heuser, Carol Stocking, Nicolaus Kröger
Primary myelofibrosis (PMF) is a hematopoietic stem cell (HSC) disease, characterized by aberrant differentiation of all myeloid lineages and profound disruption of the bone marrow niche. PMF samples carry several mutations, but their cell origin and hierarchy in regulating the different waves of clonal and aberrant myeloproliferation from the prime HSC compartment is poorly understood. Genotyping of >2000 colonies from CD133+HSC and progenitors from PMF patients confirmed the complex genetic heterogeneity within the neoplastic population...
June 15, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Daniel Fuerst, Sandra Frank, Carlheinz Mueller, Dietrich W Beelen, Johannes Schetelig, Dietger Niederwieser, Jürgen Finke, Donald Bunjes, Nicolaus Kröger, Christine Neuchel, Chrysanthi Tsamadou, Hubert Schrezenmeier, Jan Beyersmann, Joannis Mytilineos
The success of hematopoietic stem cell transplantation is determined by multiple factors. Additional complexity is conferred by covariables showing time-dependent effects. We evaluated the effect of predictors on competing-risk outcomes after hematopoietic stem cell transplantation in a time-dependent manner. We analyzed 14951 outcomes of adult patients with hematologic malignancies who underwent a first allogeneic transplant. We extended the combined endpoints of disease-free and overall survival to competing-risk settings: disease-free survival was split into relapse and non-relapse mortality...
September 2018: Haematologica
Donal P McLornan, Richard Szydlo, Marie Robin, Anja van Biezen, Linda Koster, Henrik J P Blok, Maria T Van Lint, Jürgen Finke, Antonin Vitek, Kristina Carlson, Laimonas Griskevicius, Ernst Holler, Maija Itälä-Remes, Michel Schaap, Gerard Socié, Jacques-Olivier Bay, Yves Beguin, Benedetto Bruno, Jan J Cornelissen, Tobias Gedde-Dahl, Per Ljungman, Marie T Rubio, Ibrahim Yakoub-Agha, Evgeny Klyuchnikov, Eduardo Olavarria, Yves Chalandon, Nicolaus Kröger
Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) remains the only curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the outcome and, indeed, management of those MF patients who relapse following transplant. We hereby report on the management and outcome of 202 patients who relapsed post allo-HSCT for MF.
May 29, 2018: British Journal of Haematology
Nicolaus Kröger, Sharifah Shahnaz Syed Abd Kadir, Tatjana Zabelina, Anita Badbaran, Maximilian Christopeit, Francis Ayuk, Christine Wolschke
JAK inhibition by ruxolitinib is approved for treating myelofibrosis and also has shown efficacy in treating steroid-resistant acute and chronic graft-versus-host disease (GVHD). In 12 patients with myelofibrosis (median age, 63 years; range, 43 to 71 years) who were treated with ruxolitinib and underwent allogeneic stem cell transplantation (ASCT), ruxolitinib was continued (2 × 5 mg daily) until stable engraftment. No graft failure was observed, and leukocyte engraftment was achieved after a median of 12days (range, 11 to 18 days)...
May 22, 2018: Biology of Blood and Marrow Transplantation
Anna Sureda, Peter Dreger, Michael R Bishop, Nicolaus Kroger, David L Porter
Relapse is now the major cause of treatment failure after allogeneic HSCT (alloHSCT). Many novel strategies to address this critical issue are now being developed and tested. At the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse held in Hamburg, Germany in November 2016, international experts presented and discussed recent developments in the field. Some approaches may be applicable to a wide range of patients after transplant, whereas some may be very disease-specific. We present a report from the session dedicated to issues related to prevention and treatment of relapse of lymphoid malignancies after alloHSCT...
May 24, 2018: Bone Marrow Transplantation
Nicola Gökbuget, Jonathan Canaani, Arnon Nagler, Michael Bishop, Nicolaus Kröger, David Avigan
Relapse has become the leading cause of treatment failure after stem cell transplantation. Besides cellular therapies and novel agents, immunotherapeutic strategies have entered clinical practice in order to reduce or prevent relapse. Here, we summarize the presentations on checkpoint inhibitors, vaccination strategies, and novel antibody therapies, which were presented and discussed at the third International Workshop on Biology, Prevention, and Treatment of Relapse after Stem Cell Transplantation.
June 2018: Bone Marrow Transplantation
Fred Falkenburg, Eliana Ruggiero, Chaira Bonini, David Porter, Jeff Miller, Floran Malard, Mohamad Mohty, Nicolaus Kröger, Hans Jochem Kolb
Despite recent advances in reducing therapy-related mortality after allogeneic stem cell transplantation (alloSCT) relapse remains the major cause of treatment failure and little progress has been achieved in the last decades. At the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse held in Hamburg/Germany in November 2016 international experts presented and discussed recent developments in the field. Here, the potential of cellular therapies including unspecific and specific T cells, genetically modified T cells, CAR-T cells, NK-cells, and second allografting in prevention and treatment of relapse after alloSCT are summarized...
May 24, 2018: Bone Marrow Transplantation
Sharifah Shahnaz Syed Abd Kadir, Maximilian Christopeit, Gerald Wulf, Eva Wagner, Martin Bornhauser, Thomas Schroeder, Martina Crysandt, Karin Mayer, Julia Jonas, Matthias Stelljes, Anita Badbaran, Francis Ayuketang Ayuk, Ioanna Triviai, Dominik Wolf, Christine Wolschke, Nicolaus Kröger
INTRODUCTION: Ruxolitinib is the first approved drug for treatment of myelofibrosis, but its impact of outcome after allogeneic stem cell transplantation (ASCT) is unknown. PATIENTS AND METHODS: We reported on 159 myelofibrosis patients (pts) with a median age of 59 years (r: 28-74) who received reduced intensity ASCT between 2000 and 2015 in eight German centers from related (n = 23), matched (n = 86) or mismatched (n = 50) unrelated donors. Forty-six (29%) patients received ruxolitinib at any time point prior to ASCT...
September 2018: European Journal of Haematology
Nico Gagelmann, Per Ljungman, Jan Styczynski, Nicolaus Kröger
Over the past 25 years, several randomized controlled trials have investigated the efficacy of different antiviral agents for cytomegalovirus (CMV) prophylaxis in allogeneic hematopoietic cell transplantation. We performed a systematic literature review, conventional meta-analysis, and network meta-analysis using a random-effects model and risk ratios (RRs) with corresponding 95% confidence intervals (CIs) as effect estimates. Fifteen randomized controlled trials were identified, including 7 different antiviral agents: acyclovir, ganciclovir, maribavir, brincidofovir, letermovir, valacyclovir, and vaccine...
October 2018: Biology of Blood and Marrow Transplantation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"